FDA Urges Suspension Of Glaxo's Rotarix Vaccine After PCV-1 Virus Is Detected
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency plans an advisory committee meeting in four to six weeks and, meanwhile, recommends that Merck's RotaTeq should be used instead.